IAI Proudly Introduces TAA Tabletop Series Robots

IAI (Intelligent Actuator Incorporated), a leading robotics provider headquartered in Shizuoka, Japan, would like to introduce their TTA Tabletop Series robots. The accessible tabletop design provides an affordable “in-office” option for efficient and accurate patient testing and diagnosis.

“IAI is proud to be at the forefront of technology to assist the medical community in the battle against Covid-19 and any future health crisis,” says Kaz Haruna, National Sales Manager for IAI America. The current pandemic creates an urgent need for readily available multiple testing and diagnostic tools worldwide. The IAI Tabletop Series provides clients with customizable systems that are delivered complete and functional with minimal programming required on site. The compact design is flexible, precise, and multi-use to allow the user complete control over the required operation. The TTA series is also compatible with external video processing/analysis systems for micro-dosing applications.

Currently, IAI is actively assisting the medical community by providing robotic components for infectious disease testing, molecular diagnostics, tissue and blood sampling, genomic research, cancer research, pharmaceuticals, and medical device production.

About IAI: Founded in Shimizu, Japan in 1976, Intelligent Actuator Incorporated (IAI) has over forty years of experience in the design and manufacture of customized medical and industrial robotics. Built on “Quality and Innovation,” IAI is a leader in the research and development of advanced energy-efficient and affordable Cartesian, SCARA, and Tabletop robots. From entry-level to high-speed models, IAI provides complete programmable systems and components to fulfill any and all of your medical testing and industrial production needs.

Hot this week

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”

Avery Dennison Medical Introduces Ipdated SilFoam Lite: Sustainability, MDR Certification & Performance Improvements

The newly enhanced SilFoam Lite delivers superior efficiency and reliability, bringing improved fluid handling capabilities and improved tack. These improvements make the product ideal for customers seeking quality, high-performance solutions in wound care notes Avery Dennison Medical.

Voluntary Recall Notifying Medtronic Insulin Pump Users of Potential Risks of Shortened Pump Battery Life

Medtronic plc voluntarily issued a field action starting on July 31, 2024, notifying global customers of its MiniMed™ 600 series or 700 series insulin pumps to follow their pump's built-in alerts and alarms for battery status and to contact Medtronic if they observe changes in the battery life of their pump

Medtronic Expands AiBLE Spine Surgery Ecosystem with New Technologies and Siemens Healthineers Partnership

New advancements in the AiBLE Spine Surgery ecosystem build upon the company's commitment to procedural innovation and execution